Advocacy intelligence hub — real-time data for patient organizations
Peking University — PHASE1
University Hospital, Akershus — PHASE2
M.D. Anderson Cancer Center — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
IMFINZI
(durvalumab)Orphan drugstandardAstraZeneca Pharmaceuticals LP
Programmed Death Ligand-1 Blocker [EPC]
12.1 Mechanism of Action Expression of programmed cell death ligand-1 (PD-L1) can be induced by inflammatory signals (e.g., IFN-gamma) and can be expr...
David M Gershenson, M.D
NRG Oncology
📍 HOUSTON, TX
John K Chan
NRG Oncology
Don Dizon, MD
NRG Oncology
📍 PROVIDENCE, RI
Faheez Mohamed, MBChB, MD, FRCS
Peritoneal Malignancy Unit Hampshire Hospitals NHS Foundation Trust
Robert L Coleman
NRG Oncology
📍 Anchorage, Alaska
Caio Rocha Lima, MD
Wake Forest University Health Sciences
View all Mucinous adenocarcinoma of the appendix specialists →